Operational Highlights for the First Quarter of 2026Launched a non-radioactive, full-scale, at-depth demonstration of the Company’s deep borehole waste disposal technology at Halliburton’s Drilling Technology Facility near Cameron, TX Successfully completed work under the U.S. Department of Energy Advanced Research Projects Agency-Energy’s (“ARPA-E”) Optimizing Nuclear Waste and Advanced Reactor Disposal Systems (“ONWARDS”), a project led by Oklo, Inc. Selected to participate in ARPA-E’s SCALEUP Ready program, providing up to $20 million to accelerate market adoption of Deep Isolation’s deep borehole waste disposal technology and the first time a company in the nuclear industry has been selected to participate Appointed nuclear industry veteran Ralph L. Hunter to the board of directors on January 23, 2026, Appointed...

Company Reports Record $8.8M Net Income and $19.5M Adjusted EBITDA(8) Treasury Exceeds 2.00M HYPE, 1.92M KNTQ, & 10.00M HPL Tokens as of May 11(14) HYPD’s Unique “Triple-Dip” HYPE Deployment Generated >3x Base Staking Income in Q1 Company Raises Adjusted Gross Profit(1) 2026 FY Guidance by ~20% DALLAS, May 14, 2026 (GLOBE NEWSWIRE) — Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today reported results for the first quarter ending March 31, 2026. “We are pleased to report continued scaling of our DeFi operating businesses, accretive balance sheet growth, and prudent cost management,” said Hyunsu Jung, CEO of Hyperion DeFi. Mr. Jung continued, “The opportunities to build on Hyperliquid are immense and expanding every day. More products...

MONTREAL, May 14, 2026 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the first quarter of fiscal 2026. Highlights Financial resultsHigher production and operating income in Q1-2026:Production up 12% (8% on a Combined1 basis)2 from Q1-2025, driven by new site commissioning and better wind conditions, and 1% (4%) below anticipated production;1 Operating income of $92 million ($103 million) in Q1-2026, up $27 million ($4 million) from Q1-2025; EBITDA(A)1 of $174 million ($207 million) in Q1-2026, down $2 million (up $8 million) from Q1-2025 owing mainly to a lower contribution from sites held as joint ventures, as well as to lower short-term power purchase agreement prices in France, both of which were almost entirely offset by the impact of new commissioning; Net...

Record Quarterly Revenues of $1.04 Billion, a 105% Increase from a Year Ago Excluding Bowers Acquisition, Revenues (non-GAAP) Grew by 57% from a Year Ago1 Quarterly Adjusted EBITDA (non-GAAP) Increased 132% from Prior Year2 Record Total Backlog and Awards of $5.38 Billion, 104% Increase from a Year Ago, with Q1 Book-to-Bill of 1.2x Establish Second Quarter 2026 Guidance for Revenue of $1.05 Billion – $1.1 Billion and Non-GAAP Adjusted EBITDA of $115 Million – $125 Million Raise Full Year 2026 Guidance for Revenue to $4.1 Billion – $4.3 Billion and Non-GAAP Adjusted EBITDA of $470 Million – $490 Million SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) — Legence Corp. (Nasdaq: LGN) (“Legence” or the “Company”) today reported financial results for the first quarter ended March 31, 2026. “Legence delivered a...

Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)  Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026 Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy Data Expected Mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., May 14, 2026 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical...

Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26 Pivotal RESET-Myositis® cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress PHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative...

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million Invivyd in vitro data showed continued neutralizing activity of pemivibart and VYD2311 against SARS-CoV-2 variant BA.3.2.2 (“Cicada”), confirming anticipated activity DECLARATION trial Independent Data Monitoring Committee (IDMC) ad hoc review of unblinded VYD2311 safety data resulted in IDMC recommendation for reduction of post-dose monitoring time from two hours to thirty minutes Operating expense increase quarter-over-quarter primarily attributable to DECLARATION pivotal program costs for VYD2311 for which top-line data is anticipated in Q3 2026 Strong balance sheet with Q1 2026 ending cash and cash equivalents of $184.2 million; additional ~$20 million in gross proceeds from usage...

BROOKFIELD, NEWS, May 14, 2026 (GLOBE NEWSWIRE) — Brookfield Wealth Solutions (NYSE, TSX: BNT) today announced financial results for the three months ended March 31, 2026. Sachin Shah, CEO of Brookfield Wealth Solutions, stated, “We have built a scaled and well capitalized insurance platform with a resilient portfolio of $180 billion insurance assets today. Our established U.S. platform continues to expand its product and distribution capabilities, and we are now a leader in the U.K. pension market. We look forward to further growing our international operations over time, with a focus on generating high-quality earnings and durable risk-adjusted returns for our business.”UnauditedAs of and for the periods ended March 31(US$ millions, except per share amounts) Three Months Ended  2026       2025  Total assets $ 156,059     $ 141,612  Distributable...

Sustained Focus on Execution as Transformation Progresses SKOKIE, Ill., May 14, 2026 (GLOBE NEWSWIRE) — LanzaTech Global, Inc. (NASDAQ: LNZA) (“LanzaTech” or the “Company”), a carbon management solutions company, today reported its financial and operating results for the first quarter ended March 31, 2026. Key Highlights:Successful Closing of Private Placement Financings: In January 2026, LanzaTech announced the closing of the sale and issuance of shares of its common stock to a group of investors, including new investor, SiteGround, for gross proceeds of $20.0 million and in May 2026, the Company entered into a subscription agreement with LanzaTech Global SPV, LLC, an entity controlled by a large existing investor, resulting in the immediate receipt of $10 million in gross proceeds through the issuance of 1,000,000 shares of...

IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) — Cheetah Net Supply Chain Service Inc. (“Cheetah” or the “Company”) (Nasdaq: CTNT), a logistics and warehousing services provider, today reported results for the quarter ended March 31, 2026 and provided a corporate update. For the quarter ended March 31, 2026, the Company reported revenue of $92,700 from its logistics and warehousing business, compared to $479,799 in the same period in 2025, representing a decrease of $387,099, or 80.7%. The Company recorded an operating loss of $764,319 for the quarter ended March 31, 2026, compared to an operating loss of $960,448 in the same period in 2025, representing a decrease of $196,129, or 20.4%. The decrease was primarily due to a decrease of $230,515 in selling, general and administrative expenses compared to the same period in 2025. The...